Cargando…
Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy
BACKGROUND: An increasing number of clinical trials require biomarker-driven patient stratification, especially for revolutionary immune checkpoint blockade therapy. Due to the complicated interaction between a tumor and its microenvironment, single biomarkers, such as PDL1 protein level, tumor muta...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972341/ https://www.ncbi.nlm.nih.gov/pubmed/33731020 http://dx.doi.org/10.1186/s12859-021-04050-6 |
_version_ | 1783666695043284992 |
---|---|
author | Ma, Xiaopeng Huang, Ruiqi Wu, Xikun Zhang, Pei |
author_facet | Ma, Xiaopeng Huang, Ruiqi Wu, Xikun Zhang, Pei |
author_sort | Ma, Xiaopeng |
collection | PubMed |
description | BACKGROUND: An increasing number of clinical trials require biomarker-driven patient stratification, especially for revolutionary immune checkpoint blockade therapy. Due to the complicated interaction between a tumor and its microenvironment, single biomarkers, such as PDL1 protein level, tumor mutational burden (TMB), single gene mutation and expression, are far from satisfactory for response prediction or patient stratification. Recently, combinatorial biomarkers were reported to be more precise and powerful for predicting therapy response and identifying potential target populations with superior survival. However, there is a lack of dedicated tools for such combinatorial biomarker analysis. RESULTS: Here, we present dualmarker, an R package designed to facilitate the data exploration for dual biomarker combinations. Given two biomarkers, dualmarker comprehensively visualizes their association with drug response and patient survival through 14 types of plots, such as boxplots, scatterplots, ROCs, and Kaplan–Meier plots. Using logistic regression and Cox regression models, dualmarker evaluated the superiority of dual markers over single markers by comparing the data fitness of dual-marker versus single-marker models, which was utilized for de novo searching for new biomarker pairs. We demonstrated this straightforward workflow and comprehensive capability by using public biomarker data from one bladder cancer patient cohort (IMvigor210 study); we confirmed the previously reported biomarker pair TMB/TGF-beta signature and CXCL13 expression/ARID1A mutation for response and survival analyses, respectively. In addition, dualmarker de novo identified new biomarker partners, for example, in overall survival modelling, the model with combination of HMGB1 expression and ARID1A mutation had statistically better goodness-of-fit than the model with either HMGB1 or ARID1A as single marker. CONCLUSIONS: The dualmarker package is an open-source tool for the visualization and identification of combinatorial dual biomarkers. It streamlines the dual marker analysis flow into user-friendly functions and can be used for data exploration and hypothesis generation. Its code is freely available at GitHub at https://github.com/maxiaopeng/dualmarker under MIT license. |
format | Online Article Text |
id | pubmed-7972341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79723412021-03-19 Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy Ma, Xiaopeng Huang, Ruiqi Wu, Xikun Zhang, Pei BMC Bioinformatics Software BACKGROUND: An increasing number of clinical trials require biomarker-driven patient stratification, especially for revolutionary immune checkpoint blockade therapy. Due to the complicated interaction between a tumor and its microenvironment, single biomarkers, such as PDL1 protein level, tumor mutational burden (TMB), single gene mutation and expression, are far from satisfactory for response prediction or patient stratification. Recently, combinatorial biomarkers were reported to be more precise and powerful for predicting therapy response and identifying potential target populations with superior survival. However, there is a lack of dedicated tools for such combinatorial biomarker analysis. RESULTS: Here, we present dualmarker, an R package designed to facilitate the data exploration for dual biomarker combinations. Given two biomarkers, dualmarker comprehensively visualizes their association with drug response and patient survival through 14 types of plots, such as boxplots, scatterplots, ROCs, and Kaplan–Meier plots. Using logistic regression and Cox regression models, dualmarker evaluated the superiority of dual markers over single markers by comparing the data fitness of dual-marker versus single-marker models, which was utilized for de novo searching for new biomarker pairs. We demonstrated this straightforward workflow and comprehensive capability by using public biomarker data from one bladder cancer patient cohort (IMvigor210 study); we confirmed the previously reported biomarker pair TMB/TGF-beta signature and CXCL13 expression/ARID1A mutation for response and survival analyses, respectively. In addition, dualmarker de novo identified new biomarker partners, for example, in overall survival modelling, the model with combination of HMGB1 expression and ARID1A mutation had statistically better goodness-of-fit than the model with either HMGB1 or ARID1A as single marker. CONCLUSIONS: The dualmarker package is an open-source tool for the visualization and identification of combinatorial dual biomarkers. It streamlines the dual marker analysis flow into user-friendly functions and can be used for data exploration and hypothesis generation. Its code is freely available at GitHub at https://github.com/maxiaopeng/dualmarker under MIT license. BioMed Central 2021-03-17 /pmc/articles/PMC7972341/ /pubmed/33731020 http://dx.doi.org/10.1186/s12859-021-04050-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Software Ma, Xiaopeng Huang, Ruiqi Wu, Xikun Zhang, Pei Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy |
title | Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy |
title_full | Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy |
title_fullStr | Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy |
title_full_unstemmed | Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy |
title_short | Dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy |
title_sort | dualmarker: a flexible toolset for exploratory analysis of combinatorial dual biomarkers for clinical efficacy |
topic | Software |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972341/ https://www.ncbi.nlm.nih.gov/pubmed/33731020 http://dx.doi.org/10.1186/s12859-021-04050-6 |
work_keys_str_mv | AT maxiaopeng dualmarkeraflexibletoolsetforexploratoryanalysisofcombinatorialdualbiomarkersforclinicalefficacy AT huangruiqi dualmarkeraflexibletoolsetforexploratoryanalysisofcombinatorialdualbiomarkersforclinicalefficacy AT wuxikun dualmarkeraflexibletoolsetforexploratoryanalysisofcombinatorialdualbiomarkersforclinicalefficacy AT zhangpei dualmarkeraflexibletoolsetforexploratoryanalysisofcombinatorialdualbiomarkersforclinicalefficacy |